ovarian neoplasm
Merck & Co. Announces Keytruda Achieves First Overall Survival Benefit in Resistant Ovarian Cancer
Merck & Co.; Keytruda; pembrolizumab; ovarian cancer; platinum-resistant; overall survival; checkpoint inhibitor; KEYNOTE-B96 trial; progression-free survival; PD-L1
PMV Pharma’s p53 Drug Shows Effect in Ovarian Cancer, but Financial Challenges Loom
PMV Pharmaceuticals; rezatapopt; p53; ovarian cancer; clinical trial; response rate; FDA filing; funding; cash runway
GSK Reports Mixed Results for Jemperli/Zejula Combination in First-Line Ovarian Cancer Trial
GSK, Jemperli, Zejula, ovarian cancer, first-line treatment, mixed survival data, clinical trial results
GSK’s Zejula-Jemperli Combination Achieves Primary Endpoint in Ovarian Cancer Trial, Falls Short on Overall Survival
GSK, Zejula, Jemperli, ovarian cancer, FIRST trial, progression-free survival, overall survival
Keytruda and Lynparza Combination Shows Partial Success in Ovarian Cancer Trial
Keytruda, Lynparza, ovarian cancer, clinical trial, progression-free survival, overall survival
GSK’s Zejula Fails to Meet Overall Survival Goal in First-Line Ovarian Cancer, Combination Therapy Disappoints
Zejula, niraparib, GSK, ovarian cancer, first-line treatment, overall survival, combination therapy, FDA, restriction, second-line maintenance
AbbVie Achieves Early Return on Investment with $10 Billion Immunogen Acquisition Following Phase II Ovarian Cancer Success
AbbVie, Immunogen, Ovarian Cancer, Phase II Trial, Return on Investment (ROI), Antibody-Drug Conjugate (ADC), Elahere
AbbVie’s $10.1 Billion ImmunoGen Acquisition Bears Fruit with Elahere’s Mid-Stage Success in Ovarian Cancer Treatment
AbbVie, ImmunoGen, Elahere, Ovarian Cancer, Antibody-Drug Conjugate (ADC), Clinical Trial, Acquisition, Oncology